International Journal of Radiation Oncology*Biology*Physics

Journal Information
ISSN / EISSN : 0360-3016 / 1879-355X
Current Publisher: Elsevier BV (10.1016)
Total articles ≅ 71,473
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
COMPENDEX
Archived in
SHERPA/ROMEO
EBSCO
Filter:

Latest articles in this journal

, Lucile Montagne, Shakeel Sumodhee, Renaud Schiappa, Rabia Boulahssass, Mathieu Gautier, Jocelyn Gal, Marie-Eve Chand
International Journal of Radiation Oncology*Biology*Physics; doi:10.1016/j.ijrobp.2021.03.052

The publisher has not yet granted permission to display this abstract.
Ligang Xing, Gang Wu, Luhua Wang, Jiancheng Li, Jianhua Wang, Zhiyong Yuan, Ming Chen, Yaping Xu, Xiaolong Fu, Zhengfei Zhu, et al.
International Journal of Radiation Oncology*Biology*Physics, Volume 109, pp 1349-1358; doi:10.1016/j.ijrobp.2020.11.026

The publisher has not yet granted permission to display this abstract.
Jieying Zhang, Liling Zhang, Yuhui Yang, Qing Liu, Hong Ma, Ai Huang, Yanxia Zhao, Zihan Xia, , Gang Wu
International Journal of Radiation Oncology*Biology*Physics, Volume 109, pp 1533-1546; doi:10.1016/j.ijrobp.2020.11.038

The publisher has not yet granted permission to display this abstract.
, Jérémy Godart, Thyrza Jagt, Anders Schwartz Vittrup, Lars Ulrik Fokdal, Jacob Christian Lindegaard, Nina Boje Kibsgaard Jensen, Andras Zolnay, Dominique Reijtenbagh, Petra Trnkova, et al.
International Journal of Radiation Oncology*Biology*Physics, Volume 109, pp 1580-1587; doi:10.1016/j.ijrobp.2020.11.037

The publisher has not yet granted permission to display this abstract.
, Kenji Akita, Yusuke Yamaba, Eiji Kunii, Osamu Takakuwa, Misuzu Yoshihara, Yukiko Hattori, Koichiro Nakajima, Kensuke Hayashi, Toshiyuki Toshito, et al.
International Journal of Radiation Oncology*Biology*Physics, Volume 109, pp 1359-1367; doi:10.1016/j.ijrobp.2020.11.035

The publisher has not yet granted permission to display this abstract.
Brandi Wiedmeyer, Jennifer To, Deepa. M. Sridharan, Lung-Chang Chien, Antoine M. Snijders, Hidetoshi Mori,
International Journal of Radiation Oncology*Biology*Physics, Volume 109, pp 1521-1532; doi:10.1016/j.ijrobp.2020.11.039

The publisher has not yet granted permission to display this abstract.
Kate Haslett, Neil Bayman, Kevin Franks, Nicki Groom, Susan V. Harden, Catherine Harris, Gerard Hanna, Stephen Harrow, Matthew Hatton, Paula McCloskey, et al.
International Journal of Radiation Oncology*Biology*Physics, Volume 109, pp 1341-1348; doi:10.1016/j.ijrobp.2020.11.040

Abstract:
Purpose Not all patients with stage III non-small cell lung cancer (NSCLC) are suitable for concurrent chemoradiation therapy (CRT). Local failure rate is high for sequential concurrent CRT. As such, there is a rationale for treatment intensification. Methods and Materials Isotoxic intensity modulated radiation therapy (IMRT) is a multicenter feasibility study that combines different intensification strategies including hyperfractionation, acceleration, and dose escalation facilitated by IMRT. Patients with unresectable stage III NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2, and unsuitable for concurrent CRT were recruited. A minimum of 2 cycles of platinum-based chemotherapy was compulsory before starting radiation therapy (RT). Radiation dose was increased until a maximum dose of 79.2 Gy was reached or 1 or more of the organs at risk met predefined constraints. RT was delivered in 1.8-Gy fractions twice daily, and an RT quality assurance program was implemented. The primary objective was the delivery of isotoxic IMRT to a dose >60 Gy equivalent dose in 2-Gy fractions (EQD2 assuming an α/β ratio of 10 Gy for acute reacting tissues). Results Thirty-seven patients were recruited from 7 UK centers. Median age was 69.9 years (range, 46-86 years). The male-to-female ratio was 17:18. ECOG PS was 0 to 5 in 14.2% of patients; PS was 1 to 27 in 77.1% of patients; PS was 2 to 3 in 8.6% of patients. Stage IIIA:IIIB ratio was 22:13 (62.9%:37.1%). Of 37 patients, 2 (5.4%) failed to achieve EQD2 > 60 Gy. Median prescribed tumor dose was 77.4 Gy (range, 61.2-79.2 Gy). A maximum dose of 79.2Gy was achieved in 14 patients (37.8%). Grade 3 esophagitis was reported in 2 patients, and no patients developed grade 3 to 4 pneumonitis. There were 3 grade 5 events: acute radiation pneumonitis, bronchopulmonary hemorrhage, and acute lung infection. Median follow-up at time of analysis was 25.4 months (range, 8.0-44.2) months for 11 of 35 survivors. The median survival was 18.1 months (95% confidence interval [CI], 13.9-30.6), 2-year overall survival was 33.6% (95% CI, 17.9-50.1), and progression-free survival was 23.9% (95% CI, 11.3-39.1). Conclusions Isotoxic IMRT is a well-tolerated and feasible approach to treatment intensification.
, Rachael L. Hachadorian, Michael Jermyn, Petr Bruza, Daniel A. Alexander, Irwin I. Tendler, Benjamin B. Williams, David J. Gladstone, Philip E. Schaner, Bassem I. Zaki, et al.
International Journal of Radiation Oncology*Biology*Physics, Volume 109, pp 1627-1637; doi:10.1016/j.ijrobp.2020.11.013

The publisher has not yet granted permission to display this abstract.
, Jason C. Sanders, Amy Smith, Songserea Wood, Mitchell S. Anscher, Nikole Varhegyi, Tracey L. Krupski, Timothy J. Harris, Timothy N. Showalter
International Journal of Radiation Oncology*Biology*Physics, Volume 109, pp 1254-1262; doi:10.1016/j.ijrobp.2020.11.009

The publisher has not yet granted permission to display this abstract.
, Ronny L. Rotondo, Raymond B. Mailhot Vega, Adam L. Holtzman, Wen S. Looi, Christopher G. Morris, Eric S. Sandler, Philipp R. Aldana, Julie A. Bradley
International Journal of Radiation Oncology*Biology*Physics, Volume 109, pp 1406-1413; doi:10.1016/j.ijrobp.2020.11.051

The publisher has not yet granted permission to display this abstract.
Back to Top Top